Literature DB >> 27717809

Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3.

Carmen Rodríguez-Cueto1, Mariluz Hernández-Gálvez2, Cecilia J Hillard3, Patricia Maciel4, Luis García-García5, Sara Valdeolivas1, Miguel A Pozo6, José A Ramos1, María Gómez-Ruiz7, Javier Fernández-Ruiz8.   

Abstract

Spinocerebellar ataxia type-3 (SCA-3) is a rare disease but it is the most frequent type within the autosomal dominant inherited ataxias. The disease lacks an effective treatment to alleviate major symptoms and to modify disease progression. Our recent findings that endocannabinoid receptors and enzymes are significantly altered in the post-mortem cerebellum of patients affected by autosomal-dominant hereditary ataxias suggest that targeting the endocannabinoid signaling system may be a promising therapeutic option. Our goal was to investigate the status of the endocannabinoid signaling system in a transgenic mouse model of SCA-3, in the two CNS structures most affected in this disease - cerebellum and brainstem. These animals exhibited progressive motor incoordination, imbalance, abnormal gait, muscle weakness, and dystonia, in parallel to reduced in vivo brain glucose metabolism, deterioration of specific neuron subsets located in the dentate nucleus and pontine nuclei, small changes in microglial morphology, and reduction in glial glutamate transporters. Concerning the endocannabinoid signaling, our data indicated no changes in CB2 receptors. By contrast, CB1 receptors increased in the Purkinje cell layer, in particular in terminals of basket cells, but they were reduced in the dentate nucleus. We also measured the levels of endocannabinoid lipids and found reductions in anandamide and oleoylethanolamide in the brainstem. These changes correlated with an increase in the FAAH enzyme in the brainstem, which also occurred in some cerebellar areas, whereas other endocannabinoid-related enzymes were not altered. Collectively, our results in SCA-3 mutant mice confirm a possible dysregulation in the endocannabinoid system in the most important brain structures affected in this type of ataxia, suggesting that a pharmacological manipulation addressed to correct these changes could be a promising option in SCA-3.
Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Machado-Joseph disease; autosomal-dominant inherited ataxias; cannabinoids; endocannabinoid signaling system; motor incoordination; spinocerebellar ataxia-3

Mesh:

Substances:

Year:  2016        PMID: 27717809     DOI: 10.1016/j.neuroscience.2016.09.046

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

Review 1.  The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

2.  Long-term depression of presynaptic cannabinoid receptor function at parallel fibre synapses.

Authors:  Ying Yang; Tabita Kreko-Pierce; Rebecca Howell; Jason R Pugh
Journal:  J Physiol       Date:  2019-05-13       Impact factor: 5.182

3.  Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity.

Authors:  Amir Segev; Nachshon Korem; Tomer Mizrachi Zer-Aviv; Hila Abush; Rachel Lange; Garrett Sauber; Cecilia J Hillard; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2018-06-27       Impact factor: 7.853

4.  Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.

Authors:  Guan-Yu Lin; Chung-Yung Ma; Li-Chung Kuo; Benjamin Y Hsieh; Hanbing Wang; Chin-San Liu; Mingli Hsieh
Journal:  Metab Brain Dis       Date:  2022-04-30       Impact factor: 3.655

5.  n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.

Authors:  Jui-Hao Lee; Si-Yin Lin; Jen-Wei Liu; Shinn-Zong Lin; Horng-Jyh Harn; Tzyy-Wen Chiou
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

6.  Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.

Authors:  Carmen Rodríguez-Cueto; Mariluz Hernández-Gálvez; Cecilia J Hillard; Patricia Maciel; Sara Valdeolivas; José A Ramos; María Gómez-Ruiz; Javier Fernández-Ruiz
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

Review 7.  Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets.

Authors:  María Gómez-Ruiz; Carmen Rodríguez-Cueto; Eva Luna-Piñel; Mariluz Hernández-Gálvez; Javier Fernández-Ruiz
Journal:  Front Mol Neurosci       Date:  2019-04-24       Impact factor: 5.639

8.  Subsynaptic Distribution, Lipid Raft Targeting and G Protein-Dependent Signalling of the Type 1 Cannabinoid Receptor in Synaptosomes from the Mouse Hippocampus and Frontal Cortex.

Authors:  Miquel Saumell-Esnaola; Sergio Barrondo; Gontzal García Del Caño; María Aranzazu Goicolea; Joan Sallés; Beat Lutz; Krisztina Monory
Journal:  Molecules       Date:  2021-11-16       Impact factor: 4.411

9.  Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1.

Authors:  Leyre Echeazarra; Gontzal García Del Caño; Sergio Barrondo; Imanol González-Burguera; Miquel Saumell-Esnaola; Xabier Aretxabala; Maider López de Jesús; Leire Borrega-Román; Susana Mato; Catherine Ledent; Carlos Matute; María Aranzazu Goicolea; Joan Sallés
Journal:  Histochem Cell Biol       Date:  2021-08-27       Impact factor: 4.304

10.  Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3.

Authors:  Joana Sofia Correia; Andreia Neves-Carvalho; Bárbara Mendes-Pinheiro; Joel Pires; Fábio Gabriel Teixeira; Rui Lima; Susana Monteiro; Nuno André Silva; Carina Soares-Cunha; Sofia Cravino Serra; Sara Duarte-Silva; Andreia Teixeira-Castro; António José Salgado; Patrícia Maciel
Journal:  Biomedicines       Date:  2021-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.